Page 44 - TD-1-1

Tumor Discovery A bioinformatics analysis of PD-1 in cancers

Table 2. Prognostic significance of PD‑1 mRNA in liver cancer
Clinicopathological features Overall survival Progression‑free survival Relapse‑free survival Disease specific survival
Hazard ratio P Hazard ratio P Hazard ratio P Hazard ratio P
Sex
Female 0.55 (0.30 – 1.01) 0.049 0.65 (0.39 – 1.09) 0.100 0.58 (0.32 – 1.04) 0.065 0.32 (0.15 – 0.67) 0.002
Male 0.56 (0.34 – 0.93) 0.023 0.60 (0.42 – 0.87) 0.007 0.62 (0.42 – 0.93) 0.019 0.51 (0.27 – 0.99) 0.041
TNM staging
1 2.24 (0.83 – 5.59) 0.100 1.44 (0.86 – 2.42) 0.160 0.64 (0.31 – 1.09) 0.099 1.54 (0.63 – 3.76) 0.340
1 – 2 0.75 (0.46 – 1.23) 0.260 0.61 (0.41 – 0.89) 0.001 0.57 (0.37 – 0.87) 0.008 0.61 (0.30 – 1.21) 0.150
2 0.75 (0.32 – 1.74) 0.500 0.34 (0.17 – 0.68) 0.002 0.39 (0.18 – 0.81) 0.009 0.42 (0.14 – 1.24) 0.100
2 – 3 0.66 (0.37 – 1.18) 0.160 0.54 (0.35 – 0.83) 0.004 0.55 (0.34 – 0.90) 0.015 0.48 (0.26 – 0.90) 0.019
3 1.44 (0.78 – 2.66) 0.250 0.46 (0.26 – 0.80) 0.005 0.50 (0.27 – 0.93) 0.025 0.49 (0.24 – 1.03) 0.054
3 – 4 0.70 (0.38 – 1.29) 0.250 0.46 (0.26 – 0.79) 0.004 0.50 (0.27 – 0.93) 0.025 0.48 (0.24 – 0.99) 0.041
Grade
1 0.35 (0.11 – 1.10) 0.061 0.51 (0.20 – 1.30) 0.150 2.39 (0.92 – 6.23) 0.065 0.14 (0.03 – 0.63) 0.003
2 0.63 (0.36 – 1.10) 0.110 0.58 (0.37 – 0.91) 0.0170 0.57 (0.34 – 0.95) 0.028 0.52 (0.26 – 1.06) 0.067
3 0.76 (0.39 – 1.49) 0.430 0.49 (0.30 – 0.80) 0.004 0.41 (0.24 – 0.70) 0.001 0.68 (0.30 – 1.56) 0.360
4
AJCC T
1 0.78 (0.42 – 1.44) 0.420 1.43 (0.87 – 2.38) 0.160 0.69 (0.41 – 1.18) 0.170 1.87 (0.70 – 5.04) 0.210
2 0.66 (0.31 – 1.43) 0.290 0.36 (0.19 – 0.69) 0.001 0.40 (0.19 – 0.82) 0.010 0.40 (0.15 – 1.03) 0.049
3 0.63 (0.34 – 1.19) 0.150 0.46 (0.26 – 0.82) 0.007 0.50 (0.27 – 0.95) 0.031 0.46 (0.21 – 0.99) 0.042
4
Vascular invasion
None 0.60 (0.35 – 1.03) 0.063 0.67 (0.43 – 1.04) 0.071 0.60 (0.37 – 0.98) 0.038 0.49 (0.24 – 1.03) 0.056
Micro 1.42 (0.65 – 3.11) 0.370 0.54 (0.29 – 0.99) 0.044 0.55 (0.29 – 1.03) 0.058 0.40 (0.11 – 1.46) 0.150
Race
White 0.44 (0.27 – 0.71) <0.001 0.64 (0.43 – 0.96) 0.030 0.63 (0.40 – 0.99) 0.045 0.46 (0.25 – 0.82) 0.007
Asian 0.53 (0.28 – 1.01) 0.005 0.56 (0.34 – 0.92) 0.020 0.52 (0.31 – 0.90) 0.016 0.30 (0.11 – 0.80) 0.011
Sorafenib treatment
Treated 0.36 (0.12 – 1.08) 0.059 0.40 (0.18 – 0.92) 0.027 0.35 (0.13 – 0.94) 0.029 0.36 (0.12–1.08) 0.059
Alcohol consumption
Yes 0.62 (0.32 – 1.18) 0.140 0.51 (0.30 – 0.88) 0.014 0.56 (0.31 – 1.01) 0.051 0.62 (0.30 – 1.29) 0.200
None 0.57 (0.35 – 0.91) 0.017 0.55 (0.36 – 0.84) 0.005 0.48 (0.30 – 0.76) 0.002 0.44 (0.23 – 0.85) 0.012
Hepatitis virus
Yes 0.52 (0.26 – 1.06) 0.068 0.45 (0.28 – 0.72) <0.001 0.45 (0.27 – 0.74) 0.002 0.54 (0.22 – 1.31) 0.170
None 0.70 (0.43 – 1.12) 0.130 0.70 (0.43 – 1.13) 0.140 0.61 (0.37 – 1.00) 0.048 0.59 (0.32 – 1.09) 0.090

HBV-related liver disease . Nebbia et al. have shown that tissues was positively correlated with TNM stage, tumor size,
[21]
blocking the PD-1 pathway could reduce the degree of tumor metastasis, and ascites of the patients. The results show
inflammation and fibrosis in liver tissue. After blocking the that the expression of PD-1/PD-L1 in liver cancer tissues was
Tim-3/natural ligand galectin-9 pathway, HBV-specific T related to the occurrence, development and progression of
lymphocyte immune response plays a significant regulatory liver cancer. The results suggest that PD-1/PD-L1 may play
role, indicating that the two signaling pathways of Tim-3 and an important role in the mechanism of metastasis in HCC.
PD-1 have a synergistic effect on immune suppression . The The positive rate of PD-1/PD-L1 was most pronounced in
[22]
positive expression of PD-1/PD-L1 in primary liver cancer medium-differentiated liver cancer tissues, suggesting that

Volume 1 Issue 1 (2022) 5 https://doi.org/10.36922/td.v1i1.59